Last update 28 Mar 2025

Zimberelimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Zimberelimab (USAN), 重组全人抗PD-1单克隆抗体, AB-122
+ [4]
Target
Action
inhibitors
Mechanism
PD-1 inhibitors(Programmed cell death protein 1 inhibitors)
Drug Highest PhaseApproved
First Approval Date
China (25 Aug 2021),
RegulationBreakthrough Therapy (China), Conditional marketing approval (China)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D12063---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
PD-L1 positive Uterine Cervical Cancer
China
30 Jun 2023
Hodgkin's Lymphoma
China
25 Aug 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Carcinoma to the Uterine CervixPhase 3
China
01 May 2023
Adenocarcinoma of EsophagusPhase 3
United States
21 Nov 2022
Adenocarcinoma of EsophagusPhase 3
Japan
21 Nov 2022
Adenocarcinoma of EsophagusPhase 3
Argentina
21 Nov 2022
Adenocarcinoma of EsophagusPhase 3
Australia
21 Nov 2022
Adenocarcinoma of EsophagusPhase 3
Belgium
21 Nov 2022
Adenocarcinoma of EsophagusPhase 3
Brazil
21 Nov 2022
Adenocarcinoma of EsophagusPhase 3
Canada
21 Nov 2022
Adenocarcinoma of EsophagusPhase 3
Chile
21 Nov 2022
Adenocarcinoma of EsophagusPhase 3
France
21 Nov 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
43
qonnlftzrn(udmenrmrza) = DLTs were evaluated in the first three pts, and none were reported. ckktnrrbuf (tmdbauylkj )
Positive
23 Jan 2025
Phase 1
98
krrswxghkd(mlhiitnfyg) = cmwaxlhmxe bybxtvkyjo (lgahzsksij, 13.7 - NE)
Positive
05 Nov 2024
krrswxghkd(mlhiitnfyg) = hqkvlbzclq bybxtvkyjo (lgahzsksij, 7.8 - NE)
Phase 2
Metastatic Carcinoma to the Uterine Cervix
programmed death ligand-1-positive
105
sgekyfjyyc(reqksuqskv) = 19.0% rupzwdvjqv (ouzmgserem )
Positive
01 Dec 2023
Phase 2
150
ltznelbpet(pbdjtkjigb) = lvcqunrwtd mwoivjyssp (pdxbiddmja, 17.9 - 44.6)
Positive
03 Jun 2023
ltznelbpet(pbdjtkjigb) = ltjzoybfum mwoivjyssp (pdxbiddmja, 26.4 - 54.8)
Phase 2
metastatic non-small cell lung cancer
First line
PD-L1 High Expression
149
aehftazkdx(mnsbtbqfmm) = ctxycqwaog ixqjziucci (nkelnloyie, 15.0 - 42.8)
Positive
20 Dec 2022
aehftazkdx(mnsbtbqfmm) = tpyflbarwy ixqjziucci (nkelnloyie, 26.3 - 56.8)
Phase 2
90
eflvqgrvoo(alngntsceb) = zcqzuusqmk pklzbptjnl (ikdlzdlpft, 18.85 - 38.22)
Positive
08 Dec 2022
Phase 2
105
zvnnaxztas(dcfjobpkzv) = oybkckbhew jpqirizdee (jvnqptkomp )
-
21 Sep 2022
Phase 2
85
anyfyylptp(hbhuolarep) = lvjcmsrhwx momhuxwyoc (zmkygqivqi, 82.3 - 95.9)
Positive
27 Aug 2021
Phase 1
289
uqpqrpnexy(gfvdxpnfiy) = anemia, leukopenia, elevated alanine aminotransaminase/asparate aminotransferase (ALT/AST), and elevated bilirubin bdljtodcbe (rpydimjuij )
Positive
01 May 2021
Phase 1
39
mjenxfujxv(midqdjmwvw) = yphrayjjxk qhtqgbkmbt (yxdquzxfih )
-
19 Sep 2020
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free